Quantcast

Latest Acute myeloid leukemia Stories

2014-08-12 16:28:07

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014. The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014. "We are pleased to have initiated our...

2014-08-08 11:12:02

AGA Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease (IBD) patients. These data were reported in a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA). Thiopurines are an established treatment for...

2014-08-07 20:24:36

Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug. 7, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic...

2014-08-06 08:33:56

Live Webcasts from New York on August 13th and Boston on August 14th SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: -- The Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 9:10 a.m. Eastern...

2014-07-28 08:28:49

TORONTO, July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multi-center, open-label,...

2014-07-08 08:30:12

- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today in the American Society of Hematology journal Blood. Volasertib has not been approved by the...

2014-06-16 12:29:09

Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx(TM) Portfolio CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, today announced its laboratory, located in Cambridge, MA, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services' Centers for...

2014-06-12 08:28:46

SAN DIEGO, June 12, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two poster presentations at the 19(th) Congress of the European Hematology Association (EHA), to be held June 12 through June 15, 2014, in Milan, Italy. Quizartinib (AC220) in Patients with FLT3-ITD(+) Relapsed or Refractory Acute Myeloid Leukemia: Final...

2014-06-12 04:22:18

SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor...

2014-06-10 08:31:13

Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza(®) (azacitidine) in elderly patients with newly diagnosed acute myeloid...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.